UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a healthcare organization operating through two primary segments: Optum and UnitedHealthcare. Optum delivers services across the healthcare ecosystem—including individuals, payers, providers, employers, government entities, and life sciences firms—through its three divisions: Optum Health, Optum Insight, and Optum Rx.

• Revised 2025 Outlook Reflects Medicare-Related Pressures: UnitedHealth Group (NYSE: UNH) reported its first quarter 2025 results and revised its full-year earnings guidance due to unforeseen developments primarily in its Medicare-related businesses. The company now expects full-year net earnings of USD 24.65 to USD 25.15 per share and adjusted earnings of USD 26.00 to USD 26.50 per share. This downward revision reflects two principal challenges: elevated care activity within its Medicare Advantage business, particularly in physician and outpatient services, and a less favorable member profile at Optum Health, resulting from minimal 2024 engagement by plans exiting markets and the impact of ongoing Medicare funding reductions enacted by the prior administration.
• CEO Comments on Performance and Strategic Response: Chief Executive Officer Andrew Witty acknowledged the company's underperformance relative to expectations, attributing it to external challenges and internal operational shifts. He emphasized that UnitedHealth Group is addressing these issues aggressively, with the aim of returning to its long-term targeted earnings growth rate of 13% to 16%. The company remains confident in its ability to overcome the present headwinds and position itself for sustainable future growth.
• Strong Revenue Growth and Operational Metrics: For the quarter ended March 31, 2025, UnitedHealth Group reported revenues of USD 109.6 billion, representing a USD 9.8 billion increase year-over-year. Earnings from operations reached USD 9.1 billion, while net margin improved to 5.7%. The company’s medical care ratio rose slightly to 84.8% due to elevated care costs and revenue impacts tied to Medicare reductions and member mix. Operating costs were managed effectively, with the operating cost ratio declining to 12.4% from 14.1% a year ago. Cash flows from operations stood at USD 5.5 billion, and UnitedHealth returned nearly USD 5 billion to shareholders during the quarter. Return on equity for the period was a robust 26.8%.
• UnitedHealthcare Performance Driven by Membership Growth: UnitedHealthcare, the health benefits division, posted revenues of USD 84.6 billion, up USD 9.3 billion from the prior year. Operating earnings were USD 5.2 billion, reflecting the impact of higher-than-anticipated senior care activity. The company added approximately 700,000 self-funded commercial members, driven by strong demand for its innovative solutions. However, commercial insured membership declined due to attrition in individual exchange offerings amid intense price competition. UnitedHealthcare continued to expand its footprint in state-based community plans, now serving 7.6 million members, with membership growth in Kentucky, New York, and Florida.
• Optum Shows Continued Expansion Despite Margin Pressure: Optum, the health services platform, recorded first quarter revenues of USD 63.9 billion, an increase of USD 2.8 billion year-over-year, primarily led by growth in Optum Rx. Operating earnings were USD 3.9 billion, down from USD 4.8 billion in the previous quarter, resulting in a lower operating margin of 6.1%. Optum Health generated USD 25.3 billion in revenue, supported by patient growth but offset by member mix issues and adjustments to legacy contracts. The business remains on track to serve 650,000 new value-based care patients in 2025.
• Optum Insight and Rx Deliver Innovation and Volume Growth: Optum Insight reported revenues of USD 4.6 billion, with a strong revenue backlog of USD 32.9 billion, reflecting continued demand for data-driven healthcare solutions. During the quarter, the business launched AI-powered claims processing tools that enhance productivity by more than 20% for revenue cycle management clients. Optum Rx achieved revenues of USD 35.1 billion, driven by new client wins and deepened relationships with existing clients. Prescription volume increased, with adjusted scripts reaching 408 million, compared to 395 million in the same period last year.
• Positioned for Recovery and Long-Term Growth: Despite the challenges that emerged in the first quarter, UnitedHealth Group remains committed to its strategic priorities and growth targets. The company continues to invest in technological and operational efficiencies, while expanding its consumer base across commercial, Medicare, and community plans. With proactive management responses underway, UnitedHealth expects to mitigate current issues and return to its historical performance trajectory, supported by robust fundamentals across its UnitedHealthcare and Optum businesses.

Technical Observation (on the daily chart):

UnitedHealth Group (UNH) has experienced a sharp sell-off, dropping from above USD 480 to a low near USD 297 before rebounding to around USD 316. The stock remains in a strong downtrend, trading well below its 21-day and 50-day moving averages, with the RSI at 28.9 indicating oversold conditions. A recent spike in volume suggests possible capitulation and short-term bargain buying. While a short-term bounce may continue, significant resistance lies near USD 370, and the overall trend remains bearish unless key moving averages are reclaimed.

UnitedHealth Group delivered strong first quarter 2025 results, with revenues rising 10% year-over-year to USD 109.6 billion and operating earnings reaching USD 9.1 billion, driven by expanded service reach across UnitedHealthcare and Optum. While the company revised its full-year earnings outlook due to higher Medicare care activity and reimbursement impacts, leadership is proactively addressing these issues and remains confident in returning to its long-term growth trajectory. Continued membership growth, technological innovation, and operational efficiencies underscore UnitedHealth's resilient business model and position it well for sustained value creation

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Buy’ rating has been given to UnitedHealth Group (NYSE: UNH) at the closing market price of USD 315.89 as of May 19,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 19,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.